Research progress on stereotactic body radiotherapy for oligometastatic breast cancer

VernacularTitle:寡转移性乳腺癌的立体定向放疗研究进展
Author: Yuchun SONG ¹ ; Shulian WANG
Author Information

1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科　100021
Keywords: Neoplasm oligometastasis, breast/stereotactic body radiotherapy; Research progress
From: Chinese Journal of Radiation Oncology 2021;30(11):1221-1225
CountryChina
Language:Chinese
Abstract: Distant metastasis is the leading cause of death for breast cancer patients, and advanced metastatic breast cancer is mainly considered incurable. Oligometastasis is an" intermediate stage" between local primary tumor and extensive metastasis. As a local treatment approach, radiotherapy plays an important role in the management of oligometastatic breast cancer. The development of stereotactic body radiotherapy (SBRT) allows the delivery of ablative doses to the targets without exceeding the dose constraints of organs-at-risk. Studies have shown that SBRT is safe and effective, with local control rates of more than 80% for breast cancer oligometastasis to the bone, lung, liver, brain, and lymph nodes. However, how to screen the true oligometastasis remains controversial. Randomized clinical trials will be essential to confirm whether SBRT can improve the survival outcomes.